However current therapy of kidney disease almost always entails the use of multiple agents, and it is possible that TRPC6 inhibition would be more effective if other targets were simultaneously blocked, especially in the case of diabetic nephropathy or hypertension. This evidence concerns the gene TRPC6 and hypertensive disorder.